Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites (PRECIOSA)

  • End date
    Sep 23, 2023
  • participants needed
  • sponsor
    Grifols Therapeutics LLC
Updated on 23 October 2022


This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The study population will consist of subjects being discharged after hospitalization for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or during hospitalization but without ACLF at discharge.

Condition Decompensated Cirrhosis and Ascites
Treatment Standard Medical Treatment, Albutein 20% Injectable Solution
Clinical Study IdentifierNCT03451292
SponsorGrifols Therapeutics LLC
Last Modified on23 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female subject ≥18 years of age
Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology)
Subjects who have been hospitalized for acute decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring diuretic therapy) with or without ACLF at admission or during hospitalization but without ACLF at Screening
In subjects with cirrhosis due to hepatitis B virus, decompensation must occur in the setting of continuous (no less than 3 months) appropriate antiviral therapy
In subjects with cirrhosis due to hepatitis C virus, only decompensated patients who will not receive antiviral therapy during the study period will be included (Subjects receiving antiviral therapy within 14 days prior to enrollment cannot be included in the study)
In subjects with cirrhosis due to autoimmune hepatitis, decompensation must occur in the setting of continuous immunosuppressive therapy
Subjects must be willing and able to provide written informed consent or have an authorized representative able to provide written informed consent on behalf of the subject in accordance with local law and institutional policy
CLIF-C AD score > 50 points at screening

Exclusion Criteria

Subjects with ACLF at Screening
Subjects with type 1 HRS currently on treatment with vasoconstrictors or hemodialysis
Subjects with TIPS or other surgical porto-caval shunts
Subjects with refractory ascites as defined by ICA criteria without any other event of acute decompensation
Subjects receiving dual anti-platelet therapy or anti-coagulant therapy (exception: DVT prophylaxis)
Subjects with ongoing endoscopic eradication of esophageal varices with ≤ 2 endoscopic sessions completed before screening
Subjects with evidence of current locally advanced or metastatic malignancy
Subjects with acute or chronic heart failure (New York Heart Association [NYHA])
Subjects with severe (grade III or IV) pulmonary disease (Global Obstructive Lung Disease [GOLD])
Subjects with nephropathy with renal failure with serum creatinine >2 mg/dL or systemic hypertension
Subjects with severe psychiatric disorders
Subjects with a known infection with human immunodeficiency virus (HIV) or have clinical signs and symptoms consistent with current HIV infection
Females who are pregnant, breastfeeding, or if of childbearing potential, unwilling to practice effective methods of contraception
Subjects with previous liver transplantation
Subjects with known or suspected hypersensitivity to albumin
Subjects with active drug addiction (exceptions: active alcoholism or marijuana)
Subjects participating in another clinical study within 3 months prior to screening
In the opinion of the investigator, the subject may have compliance problems with the protocol and the procedures of the protocol
Subjects with ongoing or recent variceal bleeding (subjects can be included 2 weeks after hemorrhagic episode)
Subjects with septic shock at screening
Subjects with ongoing SBP infection (subjects can be included upon resolution)
Subjects with current infection of COVID19, those who are less than 14 days post recovery, or those who have clinical signs and symptoms consistent with COVID19 infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note